Quanterix Corporation Stock price

Equities

QTRX

US74766Q1013

Advanced Medical Equipment & Technology

Delayed Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
23.56 USD +2.75% Intraday chart for Quanterix Corporation -2.73% -13.83%
Sales 2024 * 142M Sales 2025 * 167M Capitalization 897M
Net income 2024 * -38M Net income 2025 * -35M EV / Sales 2024 * 5.29 x
Net cash position 2024 * 147M Net cash position 2025 * 148M EV / Sales 2025 * 4.48 x
P/E ratio 2024 *
-23.7 x
P/E ratio 2025 *
-26.1 x
Employees 441
Yield 2024 *
-
Yield 2025 *
-
Free-Float 91.28%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Quanterix Corporation - Special Call
Scotiabank Raises Price Target on Quanterix to $32 From $30, Keeps Sector Outperform Rating MT
Quanterix Corporation Receives Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer?s Disease CI
Quanterix Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Quanterix Corporation, Q4 2023 Earnings Call, Feb 29, 2024
Quanterix Corporation Provides Earnings Guidance for the Year 2024 CI
Quanterix Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Earnings Flash (QTRX) QUANTERIX CORPORATION Reports Q4 Revenue $31.5M, vs. Street Est of $29.8M MT
Quanterix Corporation Reaffirms Earnings Guidance for the Year 2023 CI
Quanterix Announces First Collaborations with Five Health Networks to Aid the Diagnosis and Clinical Management of Individuals with Alzheimer?S Disease CI
Transcript : Quanterix Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 05:15 PM
Transcript : Quanterix Corporation, Q3 2023 Earnings Call, Nov 07, 2023
Earnings Flash (QTRX) QUANTERIX CORPORATION Reports Q3 Revenue $31.3M, vs. Street Est of $27.6M MT
Quanterix Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (QTRX) QUANTERIX CORPORATION Reports Q3 Revenue $31.3M, vs. Street Est of $27.6M MT
More news

Latest transcript on Quanterix Corporation

1 day+2.75%
1 week-2.73%
Current month-1.67%
1 month+0.34%
3 months-17.79%
6 months-15.74%
Current year-13.83%
More quotes
1 week
21.53
Extreme 21.53
24.05
1 month
21.53
Extreme 21.53
29.70
Current year
21.53
Extreme 21.53
29.70
1 year
10.64
Extreme 10.64
29.70
3 years
6.31
Extreme 6.31
69.22
5 years
6.31
Extreme 6.31
92.57
10 years
6.31
Extreme 6.31
92.57
More quotes
Managers TitleAgeSince
Chief Executive Officer 43 21-06-08
Chairman 63 10-10-31
Director of Finance/CFO 51 23-08-20
Members of the board TitleAgeSince
Chairman 63 10-10-31
Director/Board Member 59 19-07-24
Director/Board Member 59 23-01-05
More insiders
Date Price Change Volume
24-03-28 23.56 +2.75% 414,961
24-03-27 22.93 +4.70% 438,185
24-03-26 21.9 -2.54% 798,201
24-03-25 22.47 -3.69% 328,899
24-03-22 23.33 -3.67% 439,385

Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT

More quotes
Quanterix Corporation is a life sciences company. The Company is engaged in developing ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Its platforms are based on its digital Simoa detection technology. Its Simoa bead-based and planar array platforms enable customers to detect protein biomarkers in low concentrations in blood, serum, and other fluids. The Company's Simoa technology is based on traditional enzyme-linked immunosorbent assay (ELISA) technology. Its products include HD-X, SR-X, SP-X, Simoa assays and consumables, and NfL antibodies and NfL ELISA kits. It also offers contract research services for customers through its Accelerator Laboratory, which provides customers with access to Simoa technology and supports multiple projects and services, including sample testing, homebrew assay development and custom assay development. It has completed over 2,200 projects for 480 customers using its Simoa platforms.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
23.56 USD
Average target price
33 USD
Spread / Average Target
+40.07%
Consensus
  1. Stock
  2. Equities
  3. Stock Quanterix Corporation - Nasdaq